Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines

Anne Holbrook, Sam Schulman, Daniel M. Witt, Per Olav Vandvik, Jason Fish, Michael J. Kovacs, Peter J. Svensson, David L. Veenstra, Mark Crowther, Gordon H. Guyatt

Research output: Contribution to journalArticle

765 Citations (Scopus)

Abstract

Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This article focuses on the common important management questions for which, at a minimum, low-quality published evidence is available to guide best practices. Methods: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. Results: Most practical clinical questions regarding the management of anticoagulation, both oral and parenteral, have not been adequately addressed by randomized trials. We found sufficient evidence for summaries of recommendations for 23 questions, of which only two are strong rather than weak recommendations. Strong recommendations include targeting an international normalized ratio of 2.0 to 3.0 for patients on vitamin K antagonist therapy (Grade 1B) and not routinely using pharmacogenetic testing for guiding doses of vitamin K antagonist (Grade 1B). Weak recommendations deal with such issues as loading doses, initiation overlap, monitoring frequency, vitamin K supplementation, patient self-management, weight and renal function adjustment of doses, dosing decision support, drug interactions to avoid, and prevention and management of bleeding complications. We also address anticoagulation management services and intensive patient education. Conclusions: We offer guidance for many common anticoagulation-related management problems. Most anticoagulation management questions have not been adequately studied.

Original languageEnglish (US)
JournalChest
Volume141
Issue number2 SUPPL.
DOIs
StatePublished - Feb 2012

Fingerprint

Evidence-Based Practice
Practice Guidelines
Anticoagulants
Vitamin K
Thrombosis
Guidelines
International Normalized Ratio
Patient Education
Therapeutics
Self Care
Drug Interactions
Hemorrhage
Kidney
Weights and Measures

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. / Holbrook, Anne; Schulman, Sam; Witt, Daniel M.; Vandvik, Per Olav; Fish, Jason; Kovacs, Michael J.; Svensson, Peter J.; Veenstra, David L.; Crowther, Mark; Guyatt, Gordon H.

In: Chest, Vol. 141, No. 2 SUPPL., 02.2012.

Research output: Contribution to journalArticle

Holbrook, Anne ; Schulman, Sam ; Witt, Daniel M. ; Vandvik, Per Olav ; Fish, Jason ; Kovacs, Michael J. ; Svensson, Peter J. ; Veenstra, David L. ; Crowther, Mark ; Guyatt, Gordon H. / Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. In: Chest. 2012 ; Vol. 141, No. 2 SUPPL.
@article{588fd8ac1d1947e8be3856b4e065facd,
title = "Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines",
abstract = "Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This article focuses on the common important management questions for which, at a minimum, low-quality published evidence is available to guide best practices. Methods: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. Results: Most practical clinical questions regarding the management of anticoagulation, both oral and parenteral, have not been adequately addressed by randomized trials. We found sufficient evidence for summaries of recommendations for 23 questions, of which only two are strong rather than weak recommendations. Strong recommendations include targeting an international normalized ratio of 2.0 to 3.0 for patients on vitamin K antagonist therapy (Grade 1B) and not routinely using pharmacogenetic testing for guiding doses of vitamin K antagonist (Grade 1B). Weak recommendations deal with such issues as loading doses, initiation overlap, monitoring frequency, vitamin K supplementation, patient self-management, weight and renal function adjustment of doses, dosing decision support, drug interactions to avoid, and prevention and management of bleeding complications. We also address anticoagulation management services and intensive patient education. Conclusions: We offer guidance for many common anticoagulation-related management problems. Most anticoagulation management questions have not been adequately studied.",
author = "Anne Holbrook and Sam Schulman and Witt, {Daniel M.} and Vandvik, {Per Olav} and Jason Fish and Kovacs, {Michael J.} and Svensson, {Peter J.} and Veenstra, {David L.} and Mark Crowther and Guyatt, {Gordon H.}",
year = "2012",
month = "2",
doi = "10.1378/chest.11-2295",
language = "English (US)",
volume = "141",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed

T2 - American College of Chest Physicians evidence-based clinical practice guidelines

AU - Holbrook, Anne

AU - Schulman, Sam

AU - Witt, Daniel M.

AU - Vandvik, Per Olav

AU - Fish, Jason

AU - Kovacs, Michael J.

AU - Svensson, Peter J.

AU - Veenstra, David L.

AU - Crowther, Mark

AU - Guyatt, Gordon H.

PY - 2012/2

Y1 - 2012/2

N2 - Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This article focuses on the common important management questions for which, at a minimum, low-quality published evidence is available to guide best practices. Methods: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. Results: Most practical clinical questions regarding the management of anticoagulation, both oral and parenteral, have not been adequately addressed by randomized trials. We found sufficient evidence for summaries of recommendations for 23 questions, of which only two are strong rather than weak recommendations. Strong recommendations include targeting an international normalized ratio of 2.0 to 3.0 for patients on vitamin K antagonist therapy (Grade 1B) and not routinely using pharmacogenetic testing for guiding doses of vitamin K antagonist (Grade 1B). Weak recommendations deal with such issues as loading doses, initiation overlap, monitoring frequency, vitamin K supplementation, patient self-management, weight and renal function adjustment of doses, dosing decision support, drug interactions to avoid, and prevention and management of bleeding complications. We also address anticoagulation management services and intensive patient education. Conclusions: We offer guidance for many common anticoagulation-related management problems. Most anticoagulation management questions have not been adequately studied.

AB - Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This article focuses on the common important management questions for which, at a minimum, low-quality published evidence is available to guide best practices. Methods: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. Results: Most practical clinical questions regarding the management of anticoagulation, both oral and parenteral, have not been adequately addressed by randomized trials. We found sufficient evidence for summaries of recommendations for 23 questions, of which only two are strong rather than weak recommendations. Strong recommendations include targeting an international normalized ratio of 2.0 to 3.0 for patients on vitamin K antagonist therapy (Grade 1B) and not routinely using pharmacogenetic testing for guiding doses of vitamin K antagonist (Grade 1B). Weak recommendations deal with such issues as loading doses, initiation overlap, monitoring frequency, vitamin K supplementation, patient self-management, weight and renal function adjustment of doses, dosing decision support, drug interactions to avoid, and prevention and management of bleeding complications. We also address anticoagulation management services and intensive patient education. Conclusions: We offer guidance for many common anticoagulation-related management problems. Most anticoagulation management questions have not been adequately studied.

UR - http://www.scopus.com/inward/record.url?scp=84856772158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856772158&partnerID=8YFLogxK

U2 - 10.1378/chest.11-2295

DO - 10.1378/chest.11-2295

M3 - Article

C2 - 22315259

AN - SCOPUS:84856772158

VL - 141

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2 SUPPL.

ER -